MGH/Harvard is recruiting adult males with Fragile X syndrome, 18 years or older, for a neuroimaging study. Participants will be compensated up to $350.
 
The aim of the study is to examine problems with a chemical messenger called glutamate in the brain in Fragile X syndrome, and how it impacts sensory, motor and cognitive abilities and implicated structural and functional connectivity.
 
Three visits at Massachusetts General Hospital are required:
  • Medical history and behavioral testing (approx. 1.5 hours)
  • PET-MRI (approx. 2 hours)
  • Magnetoencephalography (approx. 1 hour).

The study started on March 15, 2018, and ends by June 30, 2020. The IRB approval number is 2017P001039.

Travel/time subsidy: compensation up to $350 for participation.

If you are interested, please contact:

Maria Mody, PhD
maria@nmr.mgh.harvard.edu
(617) 726-6913

Our Most Recent Opportunities
If you arrived on this page through a MyFXResearch Portal search, you can close this window and return to your filtered results. Or start a new search here.

PIXI Study: Parent-Infant Fragile X Intervention

RTI International and the University of North Carolina at Chapel Hill are conducting an early intervention study to learn about the best ways to support early development in infants identified with the full mutation of Fragile X. Babies 0–9 months old with the full mutation, and their caregivers, may be eligible to participate.

Study: Our Fragile X World Registry

Our Fragile X World collects data from families using online surveys and in-person studies. Topics covered include sensory or behavioral challenges, health care experiences, and the impact of Fragile X on families.

Fragile X Premutation Carrier Study at USC

The University of South Carolina is conducting a research study focusing on the range of language, social, and cognitive features that may be associated with variations on the FMR1 gene. Women age 35-75 who are carriers of the Fragile X premutation may be eligible to participate.